← Eichor
Study identifier: NCT05929768 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Condition: Anatomic Stage I Breast Cancer AJCC v8 · Anatomic Stage II Breast Cancer AJCC v8 · Anatomic Stage IIIA Breast Cancer AJCC v8  ·  Sponsor: SWOG Cancer Research Network

PhasePhase 3
Planned participants2400
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Alicia Aranda  ·  210-614-8808  ·  aaranda@swog.org

Dana Sparks  ·  210-614-8808  ·  dsparks@swog.org

Always discuss trial participation with your own doctor first.

Locations (963)

University of Alabama at Birmingham Cancer CenterBirmingham, Alabama, United StatesRecruiting
Anchorage Associates in Radiation MedicineAnchorage, Alaska, United StatesRecruiting
Anchorage Radiation Therapy CenterAnchorage, Alaska, United StatesSuspended
Alaska Breast Care and Surgery LLCAnchorage, Alaska, United StatesRecruiting
Alaska Oncology and Hematology LLCAnchorage, Alaska, United StatesRecruiting
Alaska Women's Cancer CareAnchorage, Alaska, United StatesRecruiting
Anchorage Oncology CentreAnchorage, Alaska, United StatesSuspended
Katmai Oncology GroupAnchorage, Alaska, United StatesRecruiting
Providence Alaska Medical CenterAnchorage, Alaska, United StatesRecruiting
Fairbanks Memorial HospitalFairbanks, Alaska, United StatesRecruiting
Kingman Regional Medical CenterKingman, Arizona, United StatesRecruiting
Cancer Center at Saint Joseph'sPhoenix, Arizona, United StatesRecruiting

+ 951 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05929768